Understanding Your CDMO: A Legal Perspective on Quality Agreements
Thursday, September 24, 2020, 1:00 PM - 2:00 PM

CDMOs are becoming increasingly assertive in their negotiation of contracts with pharmaceutical companies. This trend may be the result of the rise of the CDMO model, as well as the influx of private equity into this market segment. Regardless of the reason, pharmaceutical companies should now expect CDMOs to be more aggressive in contractually protecting themselves.

Sponsored by:

Stephen Sayre Susan Fyan